Publication of new Aveed data in Journal of Clinical Pharmacology; data evaluates dosing flexibility in men with hypogonadism.
The objective of this population PK analysis was to assess the potential impact of a more frequent dose regimen of testosterone undecanoate (8 weeks vs. 10 weeks) on exposure parameters of clinical interest.
The current FDA-approved recommended dose of Aveed is 3 mL (750 mg) injected intermuscularly, followed by 3 mL (750 mg) injected after 4 weeks, then 3 mL (750 mg) injected every 10 weeks thereafter. The findings from this PK model and simulation were published in The Journal of Clinical Pharmacology.
See-"Population Pharmacokinetic Modeling and Simulations to Evaluate a Potential Dose Regimen of Testosterone Undecanoate in Hypogonadal Males."-Alexander W. Pastuszak MD, PhD, Mark Bush PhD, Laura Curd MS, Saji Vijayan MBBS, D.Diab, Tony Priestley PhD, Qinfang Xiang PhD, Yiqun Hu MD, PhD First published: 16 July 2021 https://doi.org/10.1002/jcph.1939.